Drugs / LipovaxinS4-EAH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07647107 | Aug 2026 → Jul 2027 expected | tuberculosis | PT Bio Farma | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LipovaxinS4-EAH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647107 ↗ |
| Modality | Vaccine | “Lipovaxin Tuberculosis Vaccine” NCT07647107 ↗ |
| Route | Intramuscular | “Participants will be given two dose of 0.5 ml of Lipovaxin or control IM deltoid region of upper arm.” NCT07647107 ↗ |